Search Within

Thoracic Oncology

Formats
  1. Meeting Abstract (1709)
  2. Journal Article (1439)
  3. Review (82)
  4. Editorial (58)
  5. Book Section (35)
  6. Guidelines (25)
  7. Conference Paper (21)
  8. Correspondence (10)
  9. Research Letter (7)
  10. Miscellaneous (6)
  11. Book Whole (2)
Groups
  1. Department of Medicine (3394)
  2. Solid Tumor Oncology Division (3394)
  3. GSK Faculty (1071)
  4. Department of Pathology and Laboratory Medicine (809)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (662)
  6. Human Oncology and Pathogenesis Program (635)

More Groups

People
  1. Mark Kris (872)
  2. Alexander Drilon (637)
  3. Gregory Riely (605)
  4. Charles Rudin (495)
  5. Marc Ladanyi (418)
  6. Matthew Hellmann (412)

More People

Years
  1. 2025 (114)
  2. 2024 (271)
  3. 2023 (273)
  4. 2022 (337)
  5. 2021 (337)
  6. 2020 (258)

More Years

Publications
  1. Journal of Clinical Oncology (703)
  2. Journal of Thoracic Oncology (517)
  3. Annals of Oncology (278)
  4. Clinical Cancer Research (158)
  5. Cancer Research (128)
  6. International Journal of Radiation Oncology, Biology, Physics (89)

More Publications

Publishers
  1. American Society of Clinical Oncology (782)
  2. Elsevier Inc. (738)
  3. American Association for Cancer Research (386)
  4. Oxford University Press (352)
  5. Nature Publishing Group (156)
  6. Elsevier Science, Inc. (79)

More Publishers

Results (3394)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients
    Meeting Abstract

    Fong, L.; Forde, P. M.; Powderly, J. D.; Goldman, J. W.; Nemunaitis, J. J.; Luke, J. J.; Hellmann, M. D.; Kummar, S.; Doebele, R. C.; Mahadevan, D.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Checkmate 816: A phase 3, randomized, open-label trial of nivolumab plus ipilimumab vs platinum doublet chemotherapy as neoadjuvant treatment for early-stage NSCLC
    Meeting Abstract

    Forde, P. M.; Chaft, J. E.; Felip, E.; Broderick, S.; Girard, N.; Awad, M. M.; Kerr, K.; Blackwood-Chirchir, A.; Yang, R.; Geese, W. J.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • YES1 amplification as a mechanism of acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKIs) identified by a transposon mutagenesis screen and clinical genomic testing
    Meeting Abstract

    Fan, P. D.; Narzisi, G.; Jayaprakash, A.; Venturini, E.; Robine, N.; Smibert, P.; Germer, S.; Jordan, E.; Wang, L.; Jungbluth, A. A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Clinicopathologic features of non-small cell lung cancer (NSCLC) harboring an NTRK gene fusion
    Meeting Abstract

    Farago, A. F.; Taylor, M. S.; Doebele, R. C.; Spira, A. I.; Boyle, T. A.; Haura, E. B.; Azimi, R. S.; Shaw, A. T.; Mino-Kenudson, M.; Drilon, A. E.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Baseline frequency of brain metastases and outcomes with multikinase inhibitor therapy in patients with RET-rearranged lung cancers
    Meeting Abstract

    Drilon, A. E.; Filleron, T.; Bergagnini, I.; Milia, J.; Hatzoglou, V.; Velcheti, V.; Besse, B.; Mok, T.; Awad, M. M.; Wolf, J.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Retrospective analysis of clinical outcomes of early stage ALK-positive (ALK+) non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Dagogo-Jack, I.; Santini, F.; Eng, J.; Yeap, B. Y.; Izar, B.; Chin, E.; Litvak, A.; Jones, D. R.; Kris, M. G.; Shaw, A. T.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Financial conflicts of interest at three prominent oncology clinical pathway vendors
    Meeting Abstract

    Daly, R. M.; Bach, P.; Page, R. D.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Themes and costs underlying avoidable terminal oncology ICU hospitalizations
    Meeting Abstract

    Daly, R. M.; Hantel, A.; Polite, B. N.; Prigerson, H. G.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • EA5142 adjuvant nivolumab in resected lung cancers (ANVIL): The newest study in the ALCHEMIST platform
    Meeting Abstract

    Chaft, J. E.; Dahlberg, S. E.; Gerber, D. E.; Oxnard, G. R.; Malik, S. M.; Simone, C. B.; Edelman, M. J.; Heymach, J.; Rudin, C. M.; Ramalingam, S. S.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors
    Meeting Abstract

    Burris, H. A.; Gordon, M. S.; Hellmann, M. D.; LoRusso, P.; Emens, L. A.; Hodi, F. S.; Lieu, C. H.; Infante, J. R.; Tsai, F. Y. C.; Eder, J. P.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save